Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 26Genitourinary 16Plasma cell 10Thoracic 5Sarcoma 4Gastrointestinal 4Head & Neck 3Tumor-Agnostic 2Other solid neoplasm 2Lymphoid 2Gynecologic 2Endocrine 2Dermatologic 2Other hematologic neoplasm 1Myeloid 1

Conditions

Melanoma 2

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 194aldesleukin 148Interleukin-2 110fludarabine phosphate 106trametinib 85Temozolomide 83Dacarbazine 81fludarabine 80dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Magnetic Resonance Spectroscopy 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Specimen Handling 47Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Denosumab × Dermatologic × Clear all
NCT03620019 2026-03-27

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Completed
25 enrolled 16 charts
Dermatologic

Melanoma

NCT03161756 2022-04-07

CHARLI

Melanoma and Skin Cancer Trials Limited

Phase 1/2 Unknown
72 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡